German Court Voids AstraZeneca's Seroquel XR Patent

Law360, New York (November 14, 2012, 1:27 PM EST) -- Germany's federal patent court has invalidated an AstraZeneca AB patent covering Seroquel XR, the extended release version of its blockbuster anti-psychotic drug, the company said Tuesday.

The patent was challenged by the German unit of generic-drug maker Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd., and by Hexal AG, owned by Novartis AG. The ruling is limited to Germany and isn't binding in any other countries, AstraZeneca said.

“AstraZeneca is disappointed with the court’s decision,” it said in a statement. “The company remains committed to defending its...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.